急性骨髓性白血病市场 - 按疾病（成粒细胞、粒单核细胞、早幼粒细胞）、治疗（化疗、标靶治疗）、给药途径（口服、肠胃外）、终端使用者（医院、诊所、专科中心）和预测2024 - 2032

Acute Myeloid Leukemia Market - By Disease (Myeloblastic, Myelomonocytic, Promyelocytic), Treatment (Chemotherapy, Targeted Therapy), Route of Administration (Oral, Parenteral), End-user (Hospital, Clinic, Specialty Center) & Forecast 2024 - 2032

出版日期: 2024年01月31日 | 出版商:

Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在监管部门批准用于治疗该疾病的新药和疗法的推动下，全球急性骨髓性白血病市场规模从 2024 年到 2032 年将以 10.7% 的CAGR增长。治疗方案的快速进步和持续的研发工作为患者提供了更有效、更有针对性的治疗方法，以改善整体结果。随着新治疗选择的出现，以及现有治疗方法的优化以提高疗效，急性髓系白血病 (AML) 行业将大力关注个人化医疗和创新治疗，从而不断扩大。例如，2022 年 12 月，FDA 批准了 IDH1 抑制剂 OLU [89]，用于治疗復发或难治性 (R/R) AML。此次批准基于一项 1/2 期试验，涉及先前未接受过 IDH1 抑制剂的 IDH1 突变 R/R AML 患者

急性髓系白血病市场分为疾病类型、治疗类型、给药途径、最终用户和地区。

根据疾病类型，到 2032 年，由于其盛行率占 AML 病例的很大一部分，粒单核细胞白血病领域的行业规模将实现 11.6% 的CAGR。粒单核细胞白血病的特征是同时存在骨髓细胞和单核细胞，需要针对性的治疗方法。随着对此亚型分子机制的了解取得进展，客製化疗法正在开发中，进一步促进该细分市场的成长。

预计在 2024 年至 2032 年间，标靶治疗类型细分市场的 AML 市场规模将达到 11.4% 的CAGR。这是由于标靶治疗在治疗AML 方面的功效和特异性，与传统化疗相比，其副作用通常较少。针对 FLT3、IDH1 和 IDH2 等特定突变的药物越来越受到关注。标靶治疗开发和个人化医疗方法的不断进步，为患者提供有希望的治疗选择，也将推动该细分市场的扩张。

2024年至2032年，亚太地区急性髓性白血病市场的CAGR将达到12.3%。这一增长可归因于AML患病率的不断上升，特别是在中国和日本等国家，以及人口老龄化的加剧。医疗保健基础设施的强劲进步正在扩大该地区获得治疗选择的机会。随着对个人化医疗和创新疗法的日益关注，亚太地区将进一步成为急性髓性白血病产业的关键贡献者。

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 中东和非洲其他地区

第 10 章：公司简介

Astellas Pharma Inc.
Bristol Myers Squibb Company
Celgene Corporation
Daiichi Sankyo Company, Limited
Jazz Pharmaceuticals plc
Novartis AG
Otsuka Pharmaceutical Co., Ltd.
Partner Therapeutics, Inc.
Pfizer Inc.
Rigel Pharmaceuticals, Inc.

简介目录

Product Code: 7991

Global Acute Myeloid Leukemia Market size will grow at 10.7% CAGR from 2024 to 2032, propelled by regulatory approvals for novel drugs and therapies for the disease treatment. Rapid advancements in treatment options and the ongoing R&D efforts are providing patients with access to more effective and targeted therapies for improving the overall outcomes. With strong focus on personalized medicine and innovative treatments, the acute myeloid leukemia (AML) industry will expand as new therapeutic options emerge while the existing treatments are optimized for enhanced efficacy. For instance, in December 2022, the FDA granted approval for OLU [89], an IDH1 inhibitor, for the treatment of relapsed or refractory (R/R) AML. This approval is based on a phase 1/2 trial involving patients with IDH1-mutant R/R AML who had not previously received IDH1 inhibitors

The acute myeloid leukemia market is segmented into disease type, treatment type, route of administration, end-user, and region.

Based on disease type, the industry size from the myelomonocytic leukemia segment will achieve 11.6% CAGR up to 2032, driven by its prevalence as it accounts for a significant portion of AML cases. Myelomonocytic leukemia is characterized by the presence of both myeloid and monocytic cells, requiring targeted treatment approaches. With advancements in understanding the molecular mechanisms of this subtype, tailored therapies are being developed, further contributing to the segment growth.

AML market size from the targeted therapy treatment type segment will foresee an 11.4% CAGR between 2024 and 2032. This is due to the efficacy and specificity of targeted therapies in treating AML, which often have fewer side effects compared to traditional chemotherapy. Drugs targeting specific mutations like FLT3, IDH1, and IDH2 are gaining prominence. The ongoing advancements in targeted therapy development and personalized medicine approaches for offering promising treatment options for patients will also drive the segment expansion.

Asia Pacific acute myeloid leukemia market will register a 12.3% CAGR from 2024 to 2032. The growth can be attributed to the increasing prevalence of AML, particularly in countries like China and Japan along with the rising aging population. Robust advancements in healthcare infrastructure are expanding the access to treatment options across the region. With the growing focus on personalized medicine and innovative therapies, Asia Pacific will further emerge as a key contributor in the acute myeloid leukemia industry.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of acute myeloid leukemia
  - 3.2.1.2 Advancement in research and technology
  - 3.2.1.3 Surging government initiative and policy
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Lack of awareness and knowledge
  - 3.2.2.2 High cost associated with treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutes
- 3.5.5 Industry rivalry
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Myeloblastic leukemia
5.3 Myelomonocytic leukemia
5.4 Promyelocytic leukemia
5.5 Monocytic leukemia
5.6 Other leukemia types

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Chemotherapy
- 6.2.1 Anti-metabolites
- 6.2.2 Alkylating agents
- 6.2.3 Anthracycline drugs
- 6.2.4 Other chemotherapy types
6.3 Targeted therapy
6.4 Immunotherapy
6.5 Other treatment types

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Parenteral
7.3 Oral

Chapter 8 Market Estimates and Forecast, By End-User, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals & clinics
8.3 Specialty centers
8.4 Homecare settings
8.5 Ambulatory care centers

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 Rest of Middle East and Africa